Blog
RSS FeedPosted by Michael Wonder on 26 Nov 2019
Using GRADE methodology to assess innovation of new medicinal products in Italy
25 November 2019 - In April 2017 the Italian Medicine Agency developed new criteria to grant any new medicinal product with ...
Posted by Michael Wonder on 17 Oct 2019
Pelosi’s drug pricing plan puts medical innovation at risk
17 October 2019 - The future of medical innovation in America is at a crossroads. ...
Posted by Michael Wonder on 26 Jul 2019
Intellectual property law amends will add to business uncertainty
26 July 2019 - Medicines Australia supports efforts to strengthen Australia’s Intellectual Property arrangements to be consistent with international best ...
Posted by Michael Wonder on 22 Jul 2019
Government to invest £16 million in 'life-saving' medical advances
22 July 2019 - The Government has announced the decision to invest around £16 million in various ‘life-saving’ medical advances, ...
Posted by Michael Wonder on 14 Jul 2019
How the FDA uses science to speed medical device innovation
11 July 2019 - The MDDT program streamlines the medical device development and review process. ...
Posted by Michael Wonder on 09 Jul 2019
GSK welcomes the UK trial of subscription-style payment system for pharma companies to incentivise creation of new antibiotics
9 July 2019 - GSK is committed to tackling antimicrobial resistance as part of a sustained, multi-stakeholder response to this global ...
Posted by Michael Wonder on 09 Jul 2019
UK launches subscription style payment pilot to incentivise pharma antibiotics R&D
9 July 2019 - The UK is to try out a subscription-style payment model aimed at incentivising pharma and biotech ...
Posted by Michael Wonder on 02 Jul 2019
Innovation prizes to support cell and gene therapy
2 July 2019 - Personalised cell and gene therapy represent a fundamental therapeutic revolution. ...
Posted by Michael Wonder on 02 Jul 2019
Rebalancing high prescription drug prices with innovation incentive
1 July 2019 - The current firestorm over high drug prices didn’t start with the May 2019 approval of Novartis’s onasemnogene ...
Posted by Michael Wonder on 22 Jun 2019
Azar's plan to tie U.S. drug prices to foreign ones will impact investments in R&D
21 June 2019 - Americans, be they Republicans or Democrats, are outraged by the rising cost of prescription drugs. ...
Posted by Michael Wonder on 20 Jun 2019
Sustainable discovery and development of antibiotics — is a non-profit approach the future?
19 June 2019 - Shifting to a nonprofit-driven model for development of antibiotics could encourage discovery and development of truly needed ...
Posted by Michael Wonder on 20 Jun 2019
Drug prices and innovation
20 June 2019 - The crisis in drug pricing has reached global proportions. ...
Posted by Michael Wonder on 27 Feb 2019
Economic analysis falls short when it comes to medicines’ value
26 February 2019 - For the past two decades, a plethora of organisations identified by various innocuous acronyms (e.g., NICE) ...
Posted by Michael Wonder on 20 Feb 2019
New drug landscape dominated by high cost medicines
19 February 2019 - The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, ...
Posted by Michael Wonder on 14 Feb 2019
Quebec appeals court orders province to restore full coverage of rheumatoid-arthritis drug Remicade
13 February 2019 - Quebec’s highest court has ordered the provincial government to restore full public coverage of Remicade, an ...